Free Trial
NYSE:HIMS

Hims & Hers Health (HIMS) Stock Price, News & Analysis

Hims & Hers Health logo
$18.68 -1.05 (-5.33%)
As of 03:30 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Hims & Hers Health Stock (NYSE:HIMS)

Advanced

Key Stats

Today's Range
$18.60
▼
$19.17
50-Day Range
$19.03
▼
$30.87
52-Week Range
$13.74
▼
$40.99
Volume
7.93 million shs
Average Volume
22.25 million shs
Market Capitalization
$4.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.53
Consensus Rating
Hold

Company Overview

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products.

The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

Founded in 2017, the company initially launched its Hims brand and later introduced Hers, expanding its services to a broader audience. Co-founder Andrew Dudum serves as chief executive officer. Hims & Hers is based in the United States and has expanded into select international markets.

AI Generated. May Contain Errors.

Hims & Hers Health Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

HIMS MarketRank™: 
2.83706747978 of 5 stars

Hims & Hers Health scored higher than 57% of companies evaluated by MarketBeat, and ranked 424th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Hims & Hers Health has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 3 buy ratings, 12 hold ratings, and 1 sell rating.

  • Upside Potential

    Hims & Hers Health has a consensus price target of $31.53, representing about 66.9% upside from its current price of $18.90.

  • Amount of Analyst Coverage

    Hims & Hers Health has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Hims & Hers Health's stock forecast and price target.
  • Earnings Growth

    Earnings for Hims & Hers Health are expected to grow in the coming year, from ($0.21) to $0.03 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Hims & Hers Health is -22.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Hims & Hers Health is -22.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Hims & Hers Health has a P/B Ratio of 7.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    25.09% of the float of Hims & Hers Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Hims & Hers Health has a short interest ratio ("days to cover") of 5.84.
  • Change versus previous month

    Short interest in Hims & Hers Health has recently decreased by 3.40%, indicating that investor sentiment is improving.
  • Dividend Yield

    Hims & Hers Health does not currently pay a dividend.

  • Dividend Growth

    Hims & Hers Health does not have a long track record of dividend growth.

  • News Sentiment

    Hims & Hers Health has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 64 news articles for Hims & Hers Health this week, compared to 8 articles on an average week.
  • Search Interest

    Only 45 people have searched for HIMS on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.
  • MarketBeat Follows

    14 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,826,977.00 in company stock.

  • Percentage Held by Insiders

    11.76% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Hims & Hers Health's insider trading history.
Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HIMS Stock News Headlines

Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
What Hims & Hers Health Investors Missed Before The Fall
Hims & Hers logo overlaid on medical syringes, measuring tape, and financial charts symbolizing telehealth weight-loss market growth.
Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
Hims & Hers stock sank after a Q3 earnings and revenue miss, lower EBITDA guidance, subscriber declines, and an expanding FTC lawsuit over privacy and billing practices.
See More Headlines

HIMS Stock Analysis - Frequently Asked Questions

Hims & Hers Health's stock was trading at $32.45 at the beginning of the year. Since then, HIMS stock has decreased by 41.8% and is now trading at $18.8950.

Hims & Hers Health, Inc. (NYSE:HIMS) announced its quarterly earnings results on Monday, November, 9th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.06 by $0.03. The business's revenue for the quarter was up 48.6% on a year-over-year basis.
Read the conference call transcript
.

Hims & Hers Health's board approved a stock repurchase plan on Monday, November 17th 2025, which allows the company to buy back $250 million in outstanding shares, according to EventVestor. This means that the company could repurchase up to 3% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's management believes its shares are undervalued.

Top institutional shareholders of Hims & Hers Health include State Street Corp (3.53%), Greenfield Seitz Capital Management LLC (0.17%), Commonwealth Equity Services LLC (0.12%) and First Trust Advisors LP (0.10%). Insiders that own company stock include Melissa Baird, Michael Chi, Soleil Boughton, Oluyemi Okupe, David B Wells, Patrick Harrison Carroll, Christopher D Payne, Andrew Dudum, Garcia Andrea G Perez, Deborah M Autor, Christiane Pendarvis, Irene Becklund, Irene Becklund, Anja Manuel and Lynne Chou O'keefe.
View institutional ownership trends
.

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hims & Hers Health investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Tesla (TSLA), SoFi Technologies (SOFI), Super Micro Computer (SMCI) and Micron Technology (MU).

Company Calendar

Last Earnings
11/09/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NYSE:HIMS
CIK
1773751
Fax
N/A
Employees
2,442
Year Founded
2017

Price Target and Rating

High Price Target
$60.00
Low Price Target
$23.00
Potential Upside/Downside
+67.2%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
628.83
P/E Growth
N/A
Net Income
$128.37 million
Net Margins
-6.65%
Pretax Margin
-7.74%
Return on Equity
-9.62%
Return on Assets
-1.38%

Debt

Debt-to-Equity Ratio
3.85
Current Ratio
0.92
Quick Ratio
0.84

Sales & Book Value

Annual Sales
$2.87 billion
Price / Sales
1.53
Cash Flow
$0.80 per share
Price / Cash Flow
23.58
Book Value
$2.38 per share
Price / Book
7.93

Miscellaneous

Outstanding Shares
233,313,000
Free Float
206,845,000
Market Cap
$4.40 billion
Optionable
Optionable
Beta
2.53

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NYSE:HIMS) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners